A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

a study on Solid Tumor Non-Small Cell Lung Cancer Skin Cancer/Melanoma Cervical Cancer Multiple Myeloma Hodgkin's Lymphoma Lymphoma Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma Stomach Cancer Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Cancer Esophageal Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Official Title

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

Keywords

Advanced Solid Tumor, NSCLC, Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, DLBCL, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Non-Hodgkin Lymphoma, Zimberelimab

Eligibility

You can join if…

Open to people ages 18 years and up

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Adequate organ and marrow function

You CAN'T join if...

  • History of trauma or major surgery within 28 days prior to the first dose of study treatment.
  • Prior treatment with an anti-TIGIT antibody.
  • Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
  • Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.

  • Discontinued prior immunotherapy for immune related adverse events with a high severity.

    NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

  • University of California, Los Angeles accepting new patients
    Los Angeles California 90095 United States
  • Mayo Clinic Arizona - Mayo Clinic Hospital accepting new patients
    Phoenix Arizona 85054-4502 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Arcus Biosciences, Inc.
ID
NCT04772989
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 107 study participants
Last Updated